Trial Profile

Efficacy and safety of donepezil 23. mg/d vs. donepezil 10 mg/d in patients with moderate to severe Alzheimer's disease.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 16 Jun 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Donepezil (Primary)
Indications Alzheimer's disease
Focus Therapeutic Use
Sponsors Eisai Inc

Most Recent Events

16 Jun 2011 New trial record
14 May 2011 Results presented at the Annual Scientific Meeting of the American Geriatrics Society (2011).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com